Journal articles on the topic 'Anticancer drugs'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Anticancer drugs.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (March 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.
Reese, David M. "Anticancer drugs." Nature 378, no. 6557 (December 1995): 532. http://dx.doi.org/10.1038/378532c0.
Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, no. 1 (March 19, 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.
Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Drug Discovery 1, no. 7 (July 2002): 491–92. http://dx.doi.org/10.1038/nrd842.
Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Cancer 2, no. 9 (September 2002): 645–46. http://dx.doi.org/10.1038/nrc900.
Bibby, M. C. "Combretastatin anticancer drugs." Drugs of the Future 27, no. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.
Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (September 16, 2019): 134. http://dx.doi.org/10.3390/ph12030134.
Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update." Biomolecules 11, no. 11 (November 4, 2021): 1637. http://dx.doi.org/10.3390/biom11111637.
Zhang, Jason Y. "Apoptosis-based anticancer drugs." Nature Reviews Drug Discovery 1, no. 2 (February 2002): 101–2. http://dx.doi.org/10.1038/nrd742.
Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs." Cell Cycle 4, no. 11 (August 22, 2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.
KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, no. 1 Temporal Cont (February 1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.
Mundy, Gregory R., and Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs." New England Journal of Medicine 339, no. 6 (August 6, 1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.
Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi, and Kazumichi Andoh. "Anticancer drugs during pregnancy." Japanese Journal of Clinical Oncology 46, no. 9 (June 9, 2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.
Xing, Z., D. Li, L. Yang, Y. Xi, and X. Su. "MicroRNAs and anticancer drugs." Acta Biochimica et Biophysica Sinica 46, no. 3 (February 3, 2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.
Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz, and Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, no. 6 (March 2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.
Bradley, David. "Self-assembling anticancer drugs." Materials Today 41 (December 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.
Russell, Stephen J., and Kah-Whye Peng. "Viruses as anticancer drugs." Trends in Pharmacological Sciences 28, no. 7 (July 2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.
Kerwin, Sean. "Toward Bioengineering Anticancer Drugs." Chemistry & Biology 9, no. 9 (September 2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.
Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited." ACS Chemical Biology 1, no. 12 (December 2006): 747–50. http://dx.doi.org/10.1021/cb6004678.
Denny, William A. "Hypoxia-activated anticancer drugs." Expert Opinion on Therapeutic Patents 15, no. 6 (June 2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.
Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Cancer 14, no. 12 (November 24, 2014): 767. http://dx.doi.org/10.1038/nrc3866.
Van der Veldt, Astrid A. M., Adriaan A. Lammertsma, and Egbert F. Smit. "Scheduling of anticancer drugs." Cell Cycle 11, no. 23 (December 2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.
Mundy, Gregory R. "Bisphosphonates as anticancer drugs." Expert Opinion on Investigational Drugs 8, no. 12 (December 1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.
Bordon, Yvonne. "Anticancer drugs need bugs." Nature Reviews Immunology 14, no. 1 (December 13, 2013): 1. http://dx.doi.org/10.1038/nri3591.
Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Immunology 14, no. 12 (November 14, 2014): 776–77. http://dx.doi.org/10.1038/nri3775.
Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson, and John Zalcberg. "Discussing Expensive Anticancer Drugs." Journal of Clinical Oncology 27, no. 3 (January 20, 2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.
Schwartsmann, G. "Anticancer drugs from nature." Medical and Pediatric Oncology 37, no. 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.
Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis." Blood 136, Supplement 1 (November 5, 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.
Li, Dong Hong, Jun Lin Diao, Ke Gui Yu, and Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs." Chinese Chemical Letters 18, no. 11 (November 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.
&NA;. "Anticancer drugs from the sea." Inpharma Weekly &NA;, no. 1417 (December 2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.
Evans, William E., and Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs." Clinical Pharmacokinetics 16, no. 6 (June 1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.
Carcone, Bernard, and Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs." Sang thrombose vaisseaux 26, no. 4 (July 2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.
Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino, and Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs." Current Drug Targets 18, no. 5 (February 24, 2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.
Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner, and William D. Figg. "Thalidomide Analogues as Anticancer Drugs." Recent Patents on Anti-Cancer Drug Discovery 2, no. 2 (June 1, 2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.
Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”." Pharmaceuticals 15, no. 4 (April 14, 2022): 479. http://dx.doi.org/10.3390/ph15040479.
Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey, and Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs." Current Topics in Medicinal Chemistry 11, no. 5 (March 1, 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.
Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs." Current Drug Metabolism 7, no. 1 (January 1, 2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.
Wallace, H. M., and A. V. Fraser. "Polyamine analogues as anticancer drugs." Biochemical Society Transactions 31, no. 2 (April 1, 2003): 393–96. http://dx.doi.org/10.1042/bst0310393.
Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano, and Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs." Biological and Pharmaceutical Bulletin 36, no. 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.
Powis, Garth, Miles P. Hacker, and Graziano C. Carlon. "The Toxicity of Anticancer Drugs." Critical Care Medicine 21, no. 7 (July 1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.
Baumann, F., and R. Preiss. "Cyclophosphamide and related anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 764, no. 1-2 (November 2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.
Tjaden, U. R., and E. A. De Bruijn. "Chromatographic analysis of anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 531 (October 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.
Sapra, P., and T. M. Allen. "Ligand-targeted liposomal anticancer drugs." Progress in Lipid Research 42, no. 5 (September 2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.
Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs." Annals of Oncology 23 (October 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.
Yoshioka, T. "Drugs Interaction of Anticancer Agents." Annals of Oncology 23 (October 2012): xi65. http://dx.doi.org/10.1016/s0923-7534(20)32111-6.
Muers, Mary. "Transgenerational effects of anticancer drugs." Nature Reviews Genetics 13, no. 3 (February 14, 2012): 148. http://dx.doi.org/10.1038/nrg3190.
Gosland, Michael P., and Bert L. Lum. "The Anticancer Drugs, 2nd Edition." Annals of Pharmacotherapy 29, no. 3 (March 1995): 320. http://dx.doi.org/10.1177/106002809502900321.
Meyer, G. "Pulmonary Toxicity of Anticancer Drugs." Annals of Oncology 25 (September 2014): iv33. http://dx.doi.org/10.1093/annonc/mdu310.2.
Imran, Muhammad, Wagma Ayub, Ian S. Butler, and Zia-ur-Rehman. "Photoactivated platinum-based anticancer drugs." Coordination Chemistry Reviews 376 (December 2018): 405–29. http://dx.doi.org/10.1016/j.ccr.2018.08.009.
SALVIK, MILAN, JUN WU, and CHRISTOPHER RILEY. "Salivary Excretion of Anticancer Drugs." Annals of the New York Academy of Sciences 694, no. 1 Saliva as a D (September 1993): 319–21. http://dx.doi.org/10.1111/j.1749-6632.1993.tb18377.x.